Congratulations to LaTonya J. Hickson, Sandra M. Herrmann, Bairbre A. McNicholas and Matthew D. Griffin on their recent paper: Progress toward the clinical application of mesenchymal stromal cells and other disease-modulating regenerative therapies. The paper was published online in Kidney360 yesterday, January 27, 2021.
Congratulations to the National University of Ireland Galway and Orbsen Therapeutics team of Kevin Lynch, Oliver Treacy, Xizhe Chen, Nick Murphy, Paul Lohan, Md Nahidul Islam, Ellen Donohoe, Matthew D. Griffin, Luke Watson, Steven McLoughlin, Grace O’Malley, Aideen E. Ryan and Thomas Ritter! Their paper: TGF-b1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo was published in the journal Molecular Therapy, on the 29th of May 2020. DOI: https://doi.org/10.1016/j.ymthe.2020.05.023 Download the pdf here.
This was the 24th VISICORT-acknowledged publication. View the entire list here. Also, follow VISICORT on Research Gate.
https://visicort.eu/wp-content/uploads/2020/06/cover.tif-1.jpg329583visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2020-06-15 12:44:492020-06-15 13:20:00Galway researchers publish work in Molecular Therapy
VISICORT Coordinator Prof Matthew Griffin of the National University of Ireland Galway has recently published three papers acknowledging VISICORT work and funding:
Fazekas B and Griffin MD. “Mesenchymal stromal cell-based therapies for acute kidney injury: Progress in the last decade”, Kidney International, In Press, 2020 (Review). 28 January 2020. DOI: https://doi.org/10.1016/j.kint.2019.12.019 Pre-proof available here.
Swaminathan S and Griffin MD. Editorial: “Innovative biologics and drugs to target renal inflammation”, Frontiers Renal Pharmacol, In Press, 2020 DOI: 10.3389/fphar.2020.00038 Read the full article here.
Negi N and Griffin MD. “Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance”. Stem Cells, In Press, 29 January 2020 (Review). DOI: https://doi.org/10.1002/stem.3151 Download the pdf here.
Congratulations to Matt and his international colleagues!
https://visicort.eu/wp-content/uploads/2014/03/redeye1.jpg290300visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2020-02-03 12:44:152020-05-05 17:19:39Three new papers attributed to VISICORT!
The team of Tomás Patrick Griffin, Md Nahidul Islam, Deirdre Wall, John Ferguson, Damian Gerard Griffin, Matthew Dallas Griffin and Paula M. O’Shea from NUI Galway recently published “Plasma dephosphorylated uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential” in the December 2019 edition of the open-access journal Scientific Reports.
Congratulations to all authors!
https://visicort.eu/wp-content/uploads/2020/01/NUIG_campus.jpg163308visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2020-01-04 13:47:522020-05-05 17:19:55NUI Galway team publishes VISICORT-acknowledged study
“Human mesenchymal stromal cells broadly modulate high glucose-induced inflammatory responses of renal proximal tubular cell monolayers” authored by Md Nahidul Islam, Tomás P. Griffin, Elizabeth Sander, Stephanie Rocks, Junaid Qazi, Joana Cabral, Jasmin McCaul, Tara McMorrow and VISICORT Coordinator Prof Matthew D. Griffin at NUI Galway was published today, the 19th of November 2019. The open-access paper appears in Stem Cell Research & Therapy (2019) 10:329, DOI: 10.1186/s13287-019-1424-5 . Download the pdf here.
https://visicort.eu/wp-content/uploads/2019/06/Webp.net-resizeimage-1.jpg252820visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2019-11-19 10:27:382020-05-05 17:20:25New VISICORT-acknowledged publication from NUI Galway
Congratulations to the team! VISICORT PIs and researchers spanning the consortium have recently released a new paper in the Official Journal of the Transplantation Society. The paper entitled: “High-Risk Corneal Transplantation, Recent Developments and Future Possibilities” was released 22 August 2019. Authors are W. John Armitage, PhD; Christine Goodchild, MD; Matthew D. Griffin, DMed; David J. Gunn, FRANZCO; Jesper Hjortdal, DMSc; Paul Lohan, PhD; Conor C. Murphy, PhD; Uwe Pleyer, MD; Thomas Ritter, PhD; Derek M. Tole, FRC Ophth; Bertrand Vabres, MD.
Abstract: “Human corneal transplantation (keratoplasty) is typically considered to have superior short- and long-term outcomes and lower requirement for immunosuppression compared to solid organ transplants because of the inherent immune privilege and tolerogenic mechanisms associated with the anterior segment of the eye. However, in a substantial proportion of corneal transplants, the rates of acute rejection and/or graft failure are comparable to or greater than those of the commonly transplanted solid organs. Critically, while registry data and observational studies have helped to identify factors that are associated with increased risk of corneal transplant failure, the extent to which these risk factors operate through enhancing immune-mediated rejection is less clear. In this overview, we summarize a range of important recent clinical and basic insights related to high-risk corneal transplantation, the factors associated with graft failure and the immunological basis of corneal allograft rejection. We highlight critical research areas from which continued progress is likely to drive improvements in the long-term survival of high-risk corneal transplants. These include further development and clinical testing of predictive risk scores and assays; greater use of multicenter clinical trials to optimize immunosuppressive therapy in high-risk recipients and robust clinical translation of novel, mechanistically-targeted immunomodulatory and regenerative therapies that are emerging from basic science laboratories. We also emphasize the relative lack of knowledge regarding transplant outcomes for infection-related corneal diseases that are common in the developing world and the potential for greater cross-pollination and synergy between corneal and solid organ transplant research communities.”
Find this and all of the other VISICORT publications here.
https://visicort.eu/wp-content/uploads/2018/06/Wellcome-image-eyes-2.jpg1129760visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2019-09-06 11:34:532020-05-05 17:21:27VISICORT publication in the Official Journal of the Transplantation Society
“TNF-α/IL-1β-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung” was published online in the FASEB Journal on May 20, 2019. The authors of the study from NUI Galway are Nick Murphy, Oliver Treacy, Kevin Lynch, Maurice Morcos, Paul Lohan, Linda Howard, Gerry Fahy, Matthew D. Griffin, Aideen E. Ryan, and Thomas Ritter.
https://visicort.eu/wp-content/uploads/2019/05/fasebj.2019.33.issue-5.cover_.jpg463351visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2019-05-21 11:11:552020-05-05 17:22:12New VISICORT publication from NUI Galway team
A new study has just been published by VISICORT researchers in the leading open access journal Frontiers in Immunology today, 20 November 2018. The study “Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation” was completed by the National University of Ireland Galway team of Paul Lohan, Nick Murphy, Oliver Treacy, Kevin Lynch, Maurice Morcos, Bingling Chen, Aideen E. Ryan, Matthew D. Griffin and Thomas Ritter.
The study shows for the first time that intravenous administration of third-party allogeneic mesenchymal stromal cells (MSC from neither the new cornea recipient nor the cornea donor) results in distinct immune modulatory effects that overcome pre-existing anti-donor immunity to prolong rejection-free survival of corneal allografts in a laboratory model of high-risk corneal transplantation. The experimental cell therapy regimen described in the paper appears to be compatible with prior cryo-preservation and with co-administration of a relevant immunosuppressive drug. These findings open the door to clinical translation of “off-the-shelf” allogeneic MSC products for recipients of high-risk corneal transplants who continue to suffer from very poor long-term graft survival rates. The results of this experimental study have formed the basis of a regulatory submission for the VISICORT Phase Ib clinical trial in patients receiving a second or greater transplant who are at high risk of rejection. This trial will determine the safety and feasibility of co-administration of allogeneic MSC and MMF in the setting of high-risk corneal transplantation.
https://visicort.eu/wp-content/uploads/2014/04/nui_galway.jpg250700visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2018-11-20 11:38:002018-11-20 13:30:33New VISICORT study in Frontiers in Immunology
A VISICORT study was published recently in Stem Cells. The body of research entitled “Inter‐Species Incompatibilities Limit the Immunomodulatory Effect of Human Mesenchymal Stromal Cells in the Rat” by Paul Lohan, Oliver Treacy, Maurice Morcos, Ellen Donohoe, Yvonne O’Donoghue, Aideen E Ryan, Stephen J Elliman, Thomas Ritter and Matthew D Griffin was accepted for publication on 13 April 2018.
Abstract:
Mesenchymal stem/stromal cells (MSC) are an immunomodulatory cell population which are under pre‐clinical and clinical investigation for a number of inflammatory conditions including transplantation. In this study, a well‐established rat corneal transplantation model was used to test the ability of human MSC to prolong corneal allograft rejection‐free survival using a pre‐transplant intravenous infusion protocol previously shown to be efficacious with allogeneic rat MSC. Surprisingly, pre‐transplant administration of human MSC had no effect on corneal allograft survival. In vitro, human MSC failed to produce nitric oxide and upregulate IDO and, as a consequence, could not suppress rat T‐cell proliferation. Furthermore, human MSC were not activated by rat pro‐inflammatory cytokines. Thus, interspecies incompatibility in cytokine signalling leading to failure of MSC licensing may explain the lack of in vivo efficacy of human MSC in a rat tissue allotransplant model. Inter‐species incompatibilities should be taken into consideration when interpreting pre‐clinical data efficacy data in the context of translation to clinical trial.
https://visicort.eu/wp-content/uploads/2018/05/download.jpg82432visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2018-05-11 08:42:562019-03-20 17:34:33VISICORT study published in Stem Cells
The paper ‘Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?’ is based on the work of Dr Paul Lohan, Dr Oliver Treacy, Prof Matthew Griffin, Prof Thomas Ritter and Dr Aideen Ryan of the National University of Ireland Galway. The publication appears in the November 24, 2017, edition of Frontiers in Immunology. This research was funded by VISICORT, amongst other sources. Read the entire manuscript here.
https://visicort.eu/wp-content/uploads/2014/04/nui_galway.jpg250700visicort_adminhttp://visicort.eu/wp-content/uploads/2014/03/visicort_logo_final-300x126.jpgvisicort_admin2018-01-04 14:58:282018-01-04 14:58:28VISICORT publishes in Frontiers in Immunology
We use cookies to improve your experience on this website. We never show advertisements, but do share content from third-parties (e.g. videos) and use google analytics (we do not store any personal information).
Data about your interaction with the site is used to improve the content that we share.
You can change your mind at any time by updating your settings. Please let us know if you agree.
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Other cookies
The following cookies are also needed - You can choose if you want to allow them:
Privacy Policy
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.